1. Surgical Staging & Quality Metrics
What defines adequate lymphadenectomy, and how does node yield affect staging and treatment?
An adequate colon cancer resection should generally include at least 12 regional lymph nodes for pathological examination, together with appropriate en-bloc removal of the mesocolon and regional lymphatic drainage. Adequate node retrieval improves detection of lymph-node metastases and reduces the risk of understaging.
In this patient, 16 nodes were examined and 4 were positive, confirming pN2a (Stage III) disease. Accurate nodal staging is important because it determines the need for adjuvant chemotherapy and helps guide prognosis and treatment intensity.
2. Adjuvant Regimen Selection & Logistics
Compare 3 months of CAPOX with 6 months of FOLFOX.
The IDEA collaboration showed that 3 months of CAPOX provides similar disease-free survival to 6 months of chemotherapy for many patients with lower-risk Stage III disease (T1–3 N1). However, this patient has T3N2a disease, which is considered high-risk Stage III, so 6 months of therapy remains the more established option, particularly if using FOLFOX.
CAPOX has an important advantage in this setting: shorter treatment duration and less cumulative oxaliplatin exposure, resulting in less peripheral neuropathy. It also requires fewer hospital visits, which can reduce indirect and out-of-pocket costs. However, oral capecitabine requires reliable medication access and adherence.
For this Nigerian patient paying largely out-of-pocket, 3 months of CAPOX may be attractive if clinically appropriate and affordable, but the higher-risk N2 disease should be discussed carefully when balancing duration against toxicity and cost.
3. Biomarker Dynamics in Adjuvant vs. Metastatic Settings
Why are cetuximab/panitumumab not used in Stage III adjuvant therapy despite RAS wild-type status?
Although KRAS/NRAS wild-type status predicts sensitivity to anti-EGFR therapy in metastatic colorectal cancer, randomized trials have not demonstrated a benefit from adding cetuximab or panitumumab to standard adjuvant chemotherapy in Stage III colon cancer. Therefore, anti-EGFR therapy is not recommended in the adjuvant setting.
If he later develops synchronous liver metastases:
Primary tumour sidedness becomes important. For left-sided RAS wild-type metastatic colorectal cancer, cetuximab or panitumumab combined with chemotherapy is an important treatment option. For right-sided tumours such as this patient's cecal cancer, anti-EGFR therapy is generally less preferred, and chemotherapy plus bevacizumab or another appropriate systemic strategy is often considered.
4. dMMR/MSI-H Clinical Implications
If the tumour were dMMR/MSI-H, it would generally have a better prognosis in localized colon cancer, particularly in Stage II disease.
dMMR/MSI-H tumours have limited or no benefit from single-agent fluoropyrimidine therapy, especially in Stage II disease. In Stage III disease, however, fluoropyrimidine combined with oxaliplatin remains an important adjuvant treatment.
In advanced/metastatic disease, MSI-H/dMMR is highly clinically relevant because these tumours can respond very well to immune checkpoint inhibitors such as pembrolizumab or nivolumab-based therapy. Thus, MSI/MMR testing is important both for prognosis and treatment selection.